New York A 3833: Relates to capping cost sharing for antiviral COVID-19 therapeutics

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
A03833 Summary:

BILL NOA03833 

&nbsp

SAME ASNo Same As

&nbsp

SPONSORWeprin

&nbsp

COSPNSR

&nbsp

MLTSPNSR

&nbsp

Amd §§3216, 3221 & 4303, Ins L; amd §365-a, Soc Serv L

&nbsp

Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.

Go to top A03833 Actions:

BILL NOA03833 

&nbsp

01/30/2025referred to insurance

01/07/2026referred to insurance

Go to topA03833 Committee&nbspVotes:

Go to topA03833 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topA03833 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 3833

 2025-2026 Regular Sessions

 IN ASSEMBLY

 January 30, 2025
 ___________

 Introduced by M. of A. WEPRIN -- read once and referred to the Committee
 on Insurance

 AN ACT to amend the insurance law and the social services law, in
 relation to capping cost sharing for antiviral COVID-19 therapeutics

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. Subsection (i) of section 3216 of the insurance law is
 2 amended by adding a new paragraph 40 to read as follows:
 3 (40) (A) Every policy that provides coverage for prescription drugs
 4 shall provide coverage for antiviral therapeutics approved or granted
 5 emergency use authorization by the food and drug administration for the
 6 treatment of COVID-19 when prescribed by a licensed health care provider
 7 legally authorized to prescribe under title eight of the education law.
 8 (B) Coverage under this paragraph shall not be subject to annual
 9 deductibles or coinsurance, provided, however, that an insured who is
 10 eligible for and able to obtain prescribed antiviral therapeutics at no
 11 cost or reduced cost under a manufacturer or government program may be
 12 required to use such program before using coverage required pursuant to
 13 this paragraph.
 14 § 2. Subsection (k) of section 3221 of the insurance law is amended by
 15 adding a new paragraph 24 to read as follows:
 16 (24) (A) Every group or blanket policy delivered or issued for deliv-
 17 ery in this state that provides coverage for prescription drugs shall
 18 provide coverage for antiviral therapeutics approved or granted emergen-
 19 cy use authorization by the food and drug administration for the treat-
 20 ment of COVID-19 when prescribed by a licensed health care provider
 21 legally authorized to prescribe under title eight of the education law.
 22 (B) Coverage under this paragraph shall not be subject to annual
 23 deductibles or coinsurance, provided, however, that an insured who is
 24 eligible for and able to obtain prescribed antiviral therapeutics at no
 25 cost or reduced cost under a manufacturer or government program may be

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD07443-01-5

 A. 3833 2

 1 required to use such program before using coverage required pursuant to
 2 this paragraph.
 3 § 3. Section 4303 of the insurance law is amended by adding a new
 4 subsection (ww) to read as follows:
 5 (ww) (1) Every contract issued by a medical expense indemnity corpo-
 6 ration, a hospital service corporation, or a health service corporation
 7 that provides coverage for prescription drugs shall provide coverage for
 8 antiviral therapeutics approved or granted emergency use authorization
 9 by the food and drug administration for the treatment of COVID-19 when
 10 prescribed by a licensed health care provider legally authorized to
 11 prescribe under title eight of the education law.
 12 (2) Coverage under this subsection shall not be subject to annual
 13 deductibles or coinsurance, provided, however, that an insured who is
 14 eligible for and able to obtain prescribed antiviral therapeutics at no
 15 cost or reduced cost under a manufacturer or government program may be
 16 required to use such program before using coverage required pursuant to
 17 this subsection.
 18 § 4. Subdivision 2 of section 365-a of the social services la